Language:

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline

European journal of endocrinology, 2022-12, Vol.187 (6), p.G1-G21 [Peer Reviewed Journal]

The authors ;Copyright BioScientifica Ltd. Dec 2022 ;Attribution ;The authors 2022 The authors ;ISSN: 0804-4643 ;EISSN: 1479-683X ;DOI: 10.1530/EJE-22-0689 ;PMID: 36149449

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
Author: Husebye, Eystein S ; Castinetti, Frederik ; Criseno, Sherwin ; Curigliano, Giuseppe ; Decallonne, Brigitte ; Fleseriu, Maria ; Higham, Claire E ; Lupi, Isabella ; Paschou, Stavroula A ; Toth, Miklos ; van der Kooij, Monique ; Dekkers, Olaf M
Subjects: Clinical Practice Guideline ; Clinical practice guidelines ; Drug development ; Endocrine disorders ; Endocrinology and metabolism ; Eye diseases ; Glucocorticoids ; Human health and pathology ; Immune checkpoint inhibitors ; Immunosuppressive agents ; Life Sciences ; Patients ; Thyroid ; Thyroiditis
Is Part Of: European journal of endocrinology, 2022-12, Vol.187 (6), p.G1-G21
Description: Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated with significant autoimmune endocrinopathies that pose both diagnostic and treatment challenges. The aim of this guideline is to provide clinicians with the best possible evidence-based recommendations for treatment and follow-up of patients with ICI-induced endocrine side-effects based on the Grading of Recommendations Assessment, Development, and Evaluation system. As these drugs have been used for a relatively short time, large systematic investigations are scarce. A systematic approach to diagnosis, treatment, and follow-up is needed, including baseline tests of endocrine function before each treatment cycle. We conclude that there is no clear evidence for the benefit of high-dose glucocorticoids to treat endocrine toxicities with the possible exceptions of severe thyroid eye disease and hypophysitis affecting the visual apparatus. With the exception of thyroiditis, most endocrine dysfunctions appear to be permanent regardless of ICI discontinuation. Thus, the development of endocrinopathies does not dictate a need to stop ICI treatment.
Publisher: Bristol: Bioscientifica Ltd
Language: English
Identifier: ISSN: 0804-4643
EISSN: 1479-683X
DOI: 10.1530/EJE-22-0689
PMID: 36149449
Source: Geneva Foundation Free Medical Journals at publisher websites
Hyper Article en Ligne (HAL) (Open Access)

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline

The authors ;Copyright BioScientifica Ltd. Dec 2022 ;Attribution ;The authors 2022 The authors ;ISSN: 0804-4643 ;EISSN: 1479-683X ;DOI: 10.1530/EJE-22-0689 ;PMID: 36149449

Searching Remote Databases, Please Wait